Searchable abstracts of presentations at key conferences in endocrinology

ea0006p47 | Growth and development | SFE2003

Lanreotide Autogel in acromegaly: a pharmacokinetic and pharmacodynamic analysis

Cendros J , Peraire C , Troconiz I , Obach R

Autogel is a long-acting formulation of the somatostatin analogue lanreotide, and is effective against the symptoms of acromegaly when given by monthly deep s.c. injection. This open, Phase III, multicentre study assessed the pharmacokinetic (PK) and population PK/pharmacodynamic profile of lanreotide Autogel in patients with acromegaly who had previously received the prolonged-release (PR) formulation of lanreotide, 30mg microparticle depot formulation, given i.m.<p class...